Orforglipron improves BP, MetS status in adults with obesity

15 giờ trước
Stephen Padilla
Stephen PadillaSenior Editor; MIMS
Stephen Padilla
Stephen Padilla Senior Editor; MIMS
Orforglipron improves BP, MetS status in adults with obesity

Treatment with the oral small-molecule glucagon-like peptide-1 receptor agonist orforglipron results in significant decreases in systolic blood pressure (SBP) and resolution of metabolic syndrome (MetS) compared with placebo in adults with obesity or overweight, with or without type 2 diabetes (T2D), according to the post hoc analyses from ATTAIN-1 and ATTAIN-2 trials.

“The BP-lowering effect [of orforglipron] appeared at least in part independent of weight loss,” said study co-author Dr Luke Laffin, Cleveland Clinic Foundation, Cleveland, Ohio, US, who presented the findings at AHA 2026.

SBP reduction

Compared with placebo, orforglipron treatment for 72 weeks correlated with significant reductions in SBP in both ATTAIN-1 (‒6.1 vs ‒0.8 mm Hg) and ATTAIN-2 (‒4.9 vs ‒1.5 mm Hg) trials (p<0.001 for both). Diastolic blood pressure (DBP) also decreased substantially in ATTAIN-1 (‒2.5 vs ‒0.9 mm Hg; p<0.001) but not in ATTAIN-2 (‒1.3 vs ‒1.4 mm Hg; p=0.87). [AHA 2026, abstract 7876]

When baseline BP was categorized according to the ACC/AHA BP classification (stage 1 and 2), orforglipron showed greater BP reduction than placebo across two classes: SBP (ATTAIN-1, stage 1: ‒7.6 vs ‒1.7 mm Hg; stage 2: ‒15.9 vs ‒11.1 mm Hg; ATTAIN-2, stage 1: ‒5.6 vs ‒2.3 mm Hg; stage 2: ‒15.8 vs ‒8.2 mm Hg; p<0.001 for all) and DBP (ATTAIN-1, stage 1: ‒3.6 vs ‒2.4 mm Hg; stage 2: ‒8. Vs ‒6.7 mm Hg; ATTAIN-2, stage 1: ‒2.4 vs ‒2.1 mm Hg; stage 2: ‒6.5 vs ‒5.4 mm Hg).

In mediation analysis, weight loss accounted for about 58 percent and 80.8 percent of change in SBP in ATTAIN-1 and ATTAIN-2, respectively.

MetS resolution

For MetS, prevalence at baseline was 39.1 percent among participants randomized to orforglipron 6 mg, 39.7 percent for the 12-mg group, and 42.5 percent for the 36-mg group and 43.5 percent for placebo in ATTAIN-1. The corresponding MetS prevalence in ATTAIN-2 was 85.1 percent, 88.9 percent, 86.3 percent, and 87.9 percent. [AHA 2026, abstract 9867]

At 72 weeks, a significantly lower proportion of participants treated with orforglipron had MetS than those on placebo (ATTAIN-1, 6 mg: 23.1 percent; 12 mg: 20.0 percent; 36 mg: 19.9 percent vs 29.7 percent in placebo; ATTAIN-2, 6 mg: 54.4 percent; 12 mg: 55.7 percent; 36 mg: 46.9 percent vs 69.8 percent in placebo).

Furthermore, a significantly greater proportion of participants with MetS at baseline achieved resolution at 72 weeks with orforglipron than with placebo in the ATTAIN-1 (6 mg: 46.6 percent; 12 mg: 62.2 percent; 36 mg: 62.8 percent vs 35.5 percent in placebo; odds ratio [OR], 1.59, 2.99, and 3.07, respectively p<0.05 for all) and ATTAIN-2 (6 mg: 33.1 percent; 12 mg: 37.8 percent; 36 mg: 52.8 percent vs 15.1 percent in placebo; OR, 2.78, 3.41, and 6.27, respectively; p<0.001 for all) trials.

“These findings suggest orforglipron may offer meaningful cardiometabolic benefits beyond weight reduction alone,” said study co-author Dr Naveed Sattar, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

Study details

In these post hoc analyses of the phase III ATTAIN-1 (adults with obesity without T2D) and ATTAIN-2 (adults with obesity and T2D), Luffin and colleagues classified baseline BP using the ACC/AHA criteria as normal (<120 and <80 mm Hg), elevated (120‒129 and <80 mm Hg), stage 1 (130‒139 or 80‒89 mm Hg), or stage 2 (≥140 or ≥90 mm Hg) hypertension. They compared changes in overall BP among participants randomized to orforglipron or placebo using mixed effect for repeated measures model.

Moreover, Sattar and his team classified MetS according to the 2009 Joint Interim Statement Harmonizing the Metabolic Syndrome. MetS was characterized by the presence of at least three of the following risk factors: elevated waist circumference, blood pressure, fasting glucose, triglycerides, or reduced high-density lipoprotein cholesterol.

Changes in MetS status from baseline to week 72 in orforglipron and placebo groups were described using shift analysis of MetS status, which tracks how participants move between disease categories over time. A generalized linear mixed model was also used to analyse MetS free status postbaseline.

“Orforglipron is an oral small-molecule glucagon-like peptide-1 receptor agonist that led to clinically meaningful reductions in body weight in the ATTAIN-1 and ATTAIN-2 trials,” according to the authors.